Just six months after gaining control of the mid-stage neuropsychiatric drug sabcomeline through an acquisition of Minster Pharmaceuticals, the UK's Proximagen has inked a deal licensing out its
> While the FDA has been slammed by some drugmakers for its too-conservative approach to drug approval, it may have
OncoMed's Michael Clarke, George Q. Daly at the Harvard Stem Cell Institute, Sir Martin Evans from Cardiff University and Rene Hen from BrainCells/Columbia University are among 12 stem cell
San Diego-based BrainCells is moving its lead program into a Phase IIa trial after boosting its second venture round with a second tranche. The new money brings its second round to $50 million.